Children's Hospital of Philadelphia Research Institute, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
J Allergy Clin Immunol. 2010 May;125(5):1020-7. doi: 10.1016/j.jaci.2010.02.007. Epub 2010 Apr 14.
Chronic use of long-acting beta2-adrenergic receptor agonists (LABAs), resulting in beta2-adrenergic receptor desensitization, has been associated with increased asthma morbidity. When LABAs are used in combination with inhaled glucocorticoids, however, asthma control is improved, raising the following question: Do glucocorticoids inhibit the proasthmatic mechanism that mediates altered contractility in LABA-exposed airway smooth muscle (ASM)?
This study aimed to identify the potential protective role and mechanism of action of glucocorticoids in mitigating the effects of prolonged LABA exposure on ASM constrictor and relaxation responsiveness.
Cultured human ASM cells and isolated rabbit ASM tissues were examined for induced changes in agonist-mediated cyclic adenosine monophosphate accumulation, constrictor and relaxation responsiveness, and expression of specific glucocorticoid-regulated molecules after 24-hour exposure to the LABA salmeterol in the absence and presence of dexamethasone.
Salmeterol-exposed ASM exhibited impaired cyclic adenosine monophosphate and relaxation responses to isoproterenol and increased acetylcholine-induced contractility. These proasthmatic effects of prolonged LABA exposure were attributed to upregulated phosphodiesterase 4 (PDE4) activity and were ablated by pretreatment with dexamethasone. Further studies demonstrated that (1) dexamethasone suppressed activation of the mitogen-activated protein kinases extracellular signal-regulated kinases 1 and 2 (ERK1/2), which upregulate PDE4 expression in salmeterol-exposed ASM; and (2) the inhibitory actions of dexamethasone on salmeterol-induced ERK1/2 activation and resultant PDE4-mediated changes in ASM responsiveness were prevented by gene silencing or pharmacologic inhibition of dexamethasone-induced expression of mitogen-activated protein kinase phosphatase 1, an endogenous deactivator of ERK1/2 signaling.
Glucocorticoids prevent the adverse proasthmatic effects of prolonged LABA exposure on airway responsiveness as a result of glucocorticoid-induced upregulation of mitogen-activated protein kinase phosphatase 1, which inhibits proasthmatic ERK1/2 signaling in the LABA-exposed ASM.
慢性使用长效β2-肾上腺素能受体激动剂(LABAs)导致β2-肾上腺素能受体脱敏,与哮喘发病率增加有关。然而,当 LABA 与吸入性糖皮质激素联合使用时,哮喘控制得到改善,这就提出了一个问题:糖皮质激素是否抑制介导 LABA 暴露的气道平滑肌(ASM)收缩性改变的促哮喘机制?
本研究旨在确定糖皮质激素在减轻 LABA 暴露对 ASM 收缩和舒张反应性的影响方面的潜在保护作用和作用机制。
研究人员检测了培养的人 ASM 细胞和分离的兔 ASM 组织在 24 小时暴露于 LABA 沙美特罗后,激动剂介导的环磷酸腺苷积累、收缩和舒张反应性以及特定糖皮质激素调节分子表达的变化,同时检测了在无和有地塞米松存在的情况下。
沙美特罗暴露的 ASM 表现出环磷酸腺苷和异丙肾上腺素舒张反应受损以及乙酰胆碱诱导的收缩性增加。这些长期 LABA 暴露的促哮喘作用归因于磷酸二酯酶 4(PDE4)活性的上调,而地塞米松预处理可消除这些作用。进一步的研究表明:(1)地塞米松抑制了沙美特罗暴露的 ASM 中细胞外信号调节激酶 1 和 2(ERK1/2)的丝裂原激活蛋白激酶的激活,上调 PDE4 的表达;(2)地塞米松抑制沙美特罗诱导的 ERK1/2 激活和随后的 PDE4 介导的 ASM 反应性变化的作用,可通过基因沉默或丝裂原激活蛋白激酶磷酸酶 1 的药理学抑制来预防,后者是 ERK1/2 信号转导的内源性失活剂。
糖皮质激素通过诱导丝裂原激活蛋白激酶磷酸酶 1 的表达来防止长期 LABA 暴露对气道反应性的不利促哮喘作用,从而抑制 LABA 暴露的 ASM 中的促哮喘 ERK1/2 信号转导。